Market capitalization | $8.36m |
Enterprise Value | $-10.02m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.57 |
EV/Sales (TTM) EV/Sales | -2.31 |
P/S ratio (TTM) P/S ratio | 1.93 |
P/B ratio (TTM) P/B ratio | 0.42 |
Revenue growth (TTM) Revenue growth | -36.86% |
Revenue (TTM) Revenue | $4.33m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Aeterna Zentaris Inc.:
1 Analyst has issued a forecast Aeterna Zentaris Inc.:
Sep '24 |
+/-
%
|
||
Revenue | 4.33 4.33 |
37%
37%
|
|
Gross Profit | 1.62 1.62 |
75%
75%
|
|
EBITDA | -20 -20 |
29%
29%
|
EBIT (Operating Income) EBIT | -21 -21 |
34%
34%
|
Net Profit | -19 -19 |
21%
21%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.
Head office | Canada |
CEO | Gilles Gagnon |
Employees | 21 |
Founded | 1990 |
Website | www.aeternazentaris.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.